207 related articles for article (PubMed ID: 16841955)
1. Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.
Baillie TA
Chem Res Toxicol; 2006 Jul; 19(7):889-93. PubMed ID: 16841955
[TBL] [Abstract][Full Text] [Related]
2. Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.
Kumar S; Kassahun K; Tschirret-Guth RA; Mitra K; Baillie TA
Curr Opin Drug Discov Devel; 2008 Jan; 11(1):43-52. PubMed ID: 18175266
[TBL] [Abstract][Full Text] [Related]
3. Approaches for minimizing metabolic activation of new drug candidates in drug discovery.
Kumar S; Mitra K; Kassahun K; Baillie TA
Handb Exp Pharmacol; 2010; (196):511-44. PubMed ID: 20020275
[TBL] [Abstract][Full Text] [Related]
4. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity?
Kalgutkar AS; Didiuk MT
Chem Biodivers; 2009 Nov; 6(11):2115-37. PubMed ID: 19937848
[TBL] [Abstract][Full Text] [Related]
5. Biochemical toxicology of chemical teratogenesis.
Wells PG; Winn LM
Crit Rev Biochem Mol Biol; 1996 Feb; 31(1):1-40. PubMed ID: 8744954
[TBL] [Abstract][Full Text] [Related]
6. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites.
Wen B; Fitch WL
Expert Opin Drug Metab Toxicol; 2009 Jan; 5(1):39-55. PubMed ID: 19236228
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
9. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
Ma S; Subramanian R
J Mass Spectrom; 2006 Sep; 41(9):1121-39. PubMed ID: 16967439
[TBL] [Abstract][Full Text] [Related]
10. Toxicophores: groups and metabolic routes associated with increased safety risk.
Williams DP; Naisbitt DJ
Curr Opin Drug Discov Devel; 2002 Jan; 5(1):104-15. PubMed ID: 11865664
[TBL] [Abstract][Full Text] [Related]
11. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
Evans DC; Watt AP; Nicoll-Griffith DA; Baillie TA
Chem Res Toxicol; 2004 Jan; 17(1):3-16. PubMed ID: 14727914
[TBL] [Abstract][Full Text] [Related]
12. Strategies for dealing with reactive intermediates in drug discovery and development.
Nassar AE; Lopez-Anaya A
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):126-36. PubMed ID: 14982156
[TBL] [Abstract][Full Text] [Related]
13. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and challenges in the discovery of new central nervous system drugs.
Krause JE; Chenard BL
Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
[TBL] [Abstract][Full Text] [Related]
15. Idiosyncratic toxicity: mechanistic insights gained from analysis of prior compounds.
Waring JF; Anderson MG
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):59-65. PubMed ID: 15679173
[TBL] [Abstract][Full Text] [Related]
16. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
Masubuchi N; Makino C; Murayama N
Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
[TBL] [Abstract][Full Text] [Related]
17. Investigation of toxic metabolites during drug development.
Park K; Williams DP; Naisbitt DJ; Kitteringham NR; Pirmohamed M
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):425-34. PubMed ID: 15996699
[TBL] [Abstract][Full Text] [Related]
18. Idiosyncratic drug reactions: past, present, and future.
Uetrecht J
Chem Res Toxicol; 2008 Jan; 21(1):84-92. PubMed ID: 18052104
[TBL] [Abstract][Full Text] [Related]
19. Minimizing the potential for metabolic activation as an integral part of drug design.
Evans DC; Baillie TA
Curr Opin Drug Discov Devel; 2005 Jan; 8(1):44-50. PubMed ID: 15679171
[TBL] [Abstract][Full Text] [Related]
20. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
Baillie TA
Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
